1. Search Result
Search Result
Results for "

Cisplatin

" in MedChemExpress (MCE) Product Catalog:

201

Inhibitors & Agonists

5

Fluorescent Dye

8

Biochemical Assay Reagents

11

Peptides

5

Inhibitory Antibodies

31

Natural
Products

2

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17394
    Cisplatin
    Maximum Cited Publications
    769 Publications Verification

    cis-Platinum; CDDP; cis-Diaminodichloroplatinum

    DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Lipoxygenase Cancer
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin
  • HY-N1914
    Ergothioneine
    10+ Cited Publications

    L-(+)-Ergothioneine

    Endogenous Metabolite p38 MAPK Akt Keap1-Nrf2 NF-κB Others
    Ergothioneine is an imidazole-2-thione derivative with orally active histidine betaine. Ergothioneine is a specific inhibitor of p38-MAPK and Akt, which plays a protective role in cell apoptosis induced by stress. Ergothioneine has antioxidant activity .
    Ergothioneine
  • HY-19543
    Brusatol
    Maximum Cited Publications
    40 Publications Verification

    NSC 172924

    Keap1-Nrf2 Apoptosis Cancer
    Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent . Brusatol increases cellular apoptosis .
    Brusatol
  • HY-W010342
    6-Aminonicotinamide
    15+ Cited Publications

    NADPH Oxidase Cancer
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP +-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
    6-Aminonicotinamide
  • HY-B0303A
    Diphenhydramine hydrochloride
    5+ Cited Publications

    Histamine Receptor Endogenous Metabolite Bacterial Apoptosis Inflammation/Immunology Endocrinology Cancer
    Diphenhydramine hydrochloride is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB) .
    Diphenhydramine hydrochloride
  • HY-121608
    Lumiflavin
    1 Publications Verification

    Lumiflavine

    Fluorescent Dye Notch Cancer
    Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer .
    Lumiflavin
  • HY-131553
    D-α-Tocopherol Succinate
    3 Publications Verification

    Vitamin E succinate

    Apoptosis Cancer
    D-α-Tocopherol Succinate (Vitamin E succinate) is an antioxidant tocopherol and a salt form of vitamin E. D-α-Tocopherol Succinate inhibits Cisplatin (HY-17394)-induced cytotoxicity. D-α-Tocopherol Succinate can be used for the research of cancer .
    D-α-Tocopherol Succinate
  • HY-101255
    ODQ
    10+ Cited Publications

    Guanylate Cyclase Apoptosis Cancer
    ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells .
    ODQ
  • HY-120139
    KMH-233
    1 Publications Verification

    Amino acid Transporter Cancer
    KMH-233, a potent, reversible and selective inhibitor of l-type amino acid transporter LAT1/SLC7A5, inhibits the uptake of LAT1 substrate, l-leucin (IC50=18 μM) as well as cell growth. KMH-233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 μM) .
    KMH-233
  • HY-13700
    Nedaplatin
    1 Publications Verification

    NSC 375101D

    DNA/RNA Synthesis Cancer
    Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.
    Nedaplatin
  • HY-19536
    LLL12
    1 Publications Verification

    STAT Cancer
    LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth .
    LLL12
  • HY-N7046

    Silibinin B

    Amyloid-β Apoptosis JNK p38 MAPK Neurological Disease Cancer
    Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B
  • HY-111253

    LPL Receptor Neurological Disease
    CYM-5478 is a potent and highly selective S1P2 agonist with an EC50 of 119 nM in a TGFα-shedding assay. CYM-5478 protects neural-derived cell lines against Cisplatin toxicity .
    CYM-5478
  • HY-139696

    Aldose Reductase Cancer
    AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells .
    AKR1B10-IN-1
  • HY-44307

    Ferroptosis Cancer
    84-B10 is a 3-phenylglutaric acid derivative. 84-B10 inhibits cisplatin (HY-17394) induced tubular ferroptosis. 84-B10 attenuates cisplatin-induced mitochondrial damage and oxidative stress. 84-B10 ameliorates cisplatin-induced acute kidney injury (AKI) .
    84-B10
  • HY-N1914R

    L-(+)-Ergothioneine (Standard)

    Reference Standards Endogenous Metabolite p38 MAPK Akt Keap1-Nrf2 NF-κB Others
    Delphinidin-3-O-galactoside (chloride) (Standard) is the analytical standard of Delphinidin-3-O-galactoside (chloride). This product is intended for research and analytical applications. Delphinidin-3-O-galactoside (chloride) is an anthocyanin that extracts from wheat flour. Delphinidin-3-O-galactoside (chloride) can be used for the research of antioxidant and antimicrobial .
    Ergothioneine (Standard)
  • HY-120692

    JAK STAT Apoptosis Cancer
    Cyclanoline chloride is an alkaloid. Cyclanoline chloride can be isolated from Fangji. Cyclanoline (chloride) inhibits the phosphorylation of JAK2 and STAT3, and induces Apoptosis. Cyclanoline chloride suppresses tumor growth in subcutaneous bladder cancer xenograft models of nude mice. Cyclanoline chloride reverses cisplatin resistance in bladder cancer cells and enhances the efficacy of Cisplatin (HY-17394). Cyclanoline chloride can be used for research related to bladder cancer .
    Cyclanoline chloride
  • HY-N4327

    NF-κB Apoptosis Akt Bcl-2 Family Infection Inflammation/Immunology
    Eurycomalactone is an active quassinoid could be isolated from Eurycoma longifolia Jack. Eurycomalactone is a potent NF-κB inhibitor with an IC50 value of 0.5 μM. Eurycomalactone inhibits protein synthesis and depletes cyclin D1. Eurycomalactone enhances radiosensitivity through arrest cell cycle at G2/M phase and delayed DNA double-strand break repair. Eurycomalactone inhibits the activation of AKT/NF-κB signaling, induces apoptosis and enhances chemosensitivity to Cisplatin (HY-17394) .
    Eurycomalactone
  • HY-B1022
    Dimesna
    1 Publications Verification

    BNP-7787

    Drug Derivative Endocrinology Cancer
    Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .
    Dimesna
  • HY-D2452
    Cy3-Cisplatin
    1 Publications Verification

    Fluorescent Dye Others
    Cy3-Cisplatin is a Cyanine 3 fluorescent dye CY3 (HY-D0822) labled Cisplatin (HY-17394). Cy3-Cisplatin can be used for drug delivery, fluorescent labeling, cell imaging and tracking .
    Cy3-Cisplatin
  • HY-13816

    CDK ATM/ATR Cancer
    NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with Kis of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .
    NU6027
  • HY-116392B

    Glucosylceramide Synthase (GCS) Parasite Infection Endocrinology Cancer
    DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites .
    DL-threo-PDMP hydrochloride
  • HY-128064

    ADAC

    Adenosine Receptor Neurological Disease Inflammation/Immunology
    Adenosine amine congener (ADAC) is a selective A1 adenosine receptor agonist, can ameliorate noise- and Cisplatin-induced cochlear injury. Adenosine amine congener also has neuroprotective effects .
    Adenosine amine congener
  • HY-149508

    Keap1-Nrf2 Reactive Oxygen Species (ROS) Cancer
    Nrf2-IN-3 (Compound R16) is a small-molecule NRF2 inhibitor and increases reactive oxygen species (ROS) production. Nrf2-IN-3 selectively binds KEAP1 mutants and restores their NRF2-inhibitory function by repairing the disrupted KEAP1/NRF2 interactions, leading to proteasome-dependent NRF2 degradation in cells. Nrf2-IN-3 sensitizes KEAP1-mutated tumor cells to Cisplatin (HY-17394), Gefitinib (HY-50895), and KEAP1 G333C-mutated xenograft to Cisplatin .
    Nrf2-IN-3
  • HY-P1380A

    Apoptosis Cancer
    Difopein TFA, a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interactions. Difopein TFA is not cell permeable. Difopein TFA leads to induction of apoptosis and enhances the ability of Cisplatin (HY-17394) to kill cells .
    Difopein TFA
  • HY-147356

    DNA/RNA Synthesis Cancer
    ERCC1-XPF-IN-2 is a potent ERCC1-XPF endonuclease inhibitor with an IC50 value of 0.6 μM. ERCC1-XPF-IN-2 shows activity in nucleotide excision repair, cisplatin enhancement and γH2AX assays .
    ERCC1-XPF-IN-2
  • HY-B0019C

    SENS-401

    Phosphatase Cancer
    (R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage .
    (R)-Azasetron besylate
  • HY-129677

    TRP Channel Others
    ORC-13661 hydrochloride is a hair cell protector. ORC-13661 hydrochloride protects sensory hair cells from aminoglycoside and Cisplatin (HY-17394) ototoxicity. ORC-13661 hydrochloride is a reversibly mechanoelectrical transducer (MET) channel permeant blocker .
    ORC-13661 hydrochloride
  • HY-N2757

    Apoptosis Cancer
    7-Ketositosterol is a phytosterol isolated from the fruits of the mulberry tree (Morus alba L.). 7-Ketositosterol can significantly inhibit Cisplatin (HY-17394)-induced apoptosis in LLC-PK1 cells and has the potential to improve Cisplatin-induced nephrotoxicity .
    7-Ketositosterol
  • HY-15266

    PRI 2202; Impurity D of Calcipotriol

    Drug Derivative VD/VDR Cancer
    24R-Calcipotriol (PRI 2202; Impurity D of Calcipotriol), an isomer of Calcipotriol (HY-10001), is a synthetic vitamin D analog. 24R-Calcipotriol exhibits synergistic antiproliferative effects with low-dose cytostatics in in vitro. 24R-Calcipotriol produces tumor growth inhibition when combined with Cyclophosphamide (HY-17420) and Cisplatin (HY-17394) in mice models. 24R-Calcipotriol can increase serum calcium levels and reduce blood leukocyte counts . 24R-Calcipotriol can be used for the research of mammary cancer and Lewis lung cancer .
    24R-Calcipotriol
  • HY-W096169D

    Biochemical Assay Reagents Drug Intermediate Cancer
    Platinum is a metallic element, and its complexes act as orally active anticancer agents. Platinum-based complexes used for tumors include Cisplatin (HY-17394), Carboplatin (HY-17393), and Oxaliplatin (HY-17371) .
    Platinum
  • HY-W075885

    trans-platinumdiamminedichloride

    DNA Alkylator/Crosslinker Others
    trans-Platinum(II)diammine dichloride (trans-platinumdiamminedichloride) is a geometric isomer of Cisplatin (HY-17394). Trans-Platinum(II)diammine dichloride is a DNA cross-linking agent that induces significant DNA cross-link damage while exhibiting low cytotoxicity. Trans-Platinum(II)diammine dichloride is useful for studying DNA-protein cross-links .
    trans-Platinum(II)diammine dichloride
  • HY-142956

    Reactive Oxygen Species (ROS) Cancer
    ROS-ERS inducer 1 is a type II ICD (immunogenic cell death) inducer. ROS-ERS inducer 1 is a Pt(II)-N-heterocyclic carbene (Pt(II)-NHC) complex derived from 4,5-diarylimidazole. ROS-ERS inducer 1 successfully induces endoplasmic reticulum stress (ERS) accompanied by reactive oxygen species (ROS) generation and finally lead to the release of damage-associated molecular patterns (DAMPs) in HCC cells. ROS-ERS inducer 1 displays much higher anticancer activities than Cisplatin .
    ROS-ERS inducer 1
  • HY-148365

    Mixed Lineage Kinase RIP kinase CDK Cancer
    NecroIr1 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and Mixed Lineage Kinase (MLKL), and regulates CDK4 expression .
    NecroIr1
  • HY-148366

    Mixed Lineage Kinase RIP kinase CDK Cancer
    NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), and regulates CDK4 expression .
    NecroIr2
  • HY-D2438

    Fluorescent Dye Cancer
    CDDP-PEG-Cy3 is a CDDP-PEG conjugate labeled with Cy3 (HY-D0822). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Cisplatin (CDDP) (HY-17394) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    CDDP-PEG-Cy3
  • HY-106588

    SKI 2053R

    DNA Alkylator/Crosslinker Cancer
    Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles .
    Heptaplatin
  • HY-117082

    GBL-5g

    TNF Receptor Inflammation/Immunology
    UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors .
    UTL-5g
  • HY-163506

    Apoptosis Ferroptosis Others
    Ebselen derivative 1 (Compound 19) is a glutathione peroxidase (GPx) mimic with oral activity. Ebselen derivative 1 demonstrates significant protective effects against cisplatin (HY-17394)-induced hair cell (HC) damage both in vitro and in vivo, effectively reducing oxidative stress, apoptosis, and ferroptosis in hair cells. Ebselen derivative 1 can be utilized in the research of cisplatin (HY-17394)-induced hearing loss .
    Ebselen derivative 1
  • HY-179026

    Calcium Channel P-glycoprotein Apoptosis Bacterial Infection Cancer
    HCA-6 is a calcium-channel and P-glycoprotein blocker. HCA-6 can induce cancer cells apoptosis and increase anticancer activity of Cisplatin (HY-17394). HCA-6 also exhibits antibacterial activity against Bacillus subtilis. HCA-6 can be used for the research of cancer and infection, such as breast cancer .
    HCA-6
  • HY-175812

    Endonuclease Cancer
    MU876 (Compound 32) is a MUS81 inhibitor with an IC50 of 0.5  μM. MU876 effectively inhibits MUS81-dependent homologous recombination (HR) and break-induced replication (BIR) pathways. MU876 sensitizes cancer cells to DNA-damaging agents, such as Cisplatin (HY-17394), through impairing their ability to repair DNA lesions. MU876 can be used for cancers chemotherapy research .
    MU876
  • HY-P11053

    HSP Cancer
    A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin (HY-17394). A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma .
    A17 peptide
  • HY-161687

    Src Cancer
    Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .
    Cisplatin/Dasatinib prodrug-1
  • HY-105253

    PARP Neurological Disease
    PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent PARP inhibitor with Kis of 2 and 5 nM against PARP-2 and PARP-1, respectively. PARP-2/1-IN-2 has an EC50 of 3 nM in a cell based assay of PARP activity .
    PARP-2/1-IN-2
  • HY-N10313

    Bcl-2 Family Keap1-Nrf2 Apoptosis Cancer
    Dehydrobruceine B, a quassinoid, can be isolated from Brucea javanica. Dehydrobruceine B shows a synergistic effect with Cisplatin (HY-17394) to induce apoptosis via mitochondrial method. Dehydrobruceine B increases apoptosis-inducing factor (AIF) and Bax expression and suppresses Keap1-Nrf2 .
    Dehydrobruceine B
  • HY-178261

    Glutathione S-transferase Cancer
    KT53 is a highly active, selective, and cell penetrable GSTO1 inhibitor. KT53 can effectively inhibit GSTO1 activity in MDA-MB-435 (IC50 = 35 nM) cells. KT53 significantly enhances the killing effect of cisplatin (HY-17394) on MDA-MB-435 cancer cells. KT53 can be used for cancer research .
    KT53
  • HY-P11052

    HSP Cancer
    A8 peptide is a Hsp72 antagonist. A8 peptide inhibits tumor progression and metastasis as well as enhances the cancer cells' sensitivity to apoptosis induced by chemotherapeutic agents (such as Cisplatin (HY-17394)) by blocking the Hsp72-TLR2 interaction and the subsequent activation of MDSCs. A8 peptide can be used for cancers research .
    A8 peptide
  • HY-176836

    Endonuclease Cancer
    PNR-3-82 is a selective Apoptotic endonuclease G (EndoG) inhibitor with an IC50 of 0.61  μM for EndoG over DNase I. PNR-3-82 does not inhibit five cell death-related enzymes including DNase II, RNase A, proteinase, lactate dehydrogenase and superoxide dismutase 1. PNR-3-82 has a cytoprotective activity and blocks Cisplatin (HY-17394) and Docetaxel (HY-B0011)-induced cell death. PNR-3-82 can be used for cell injuries research .
    PNR-3-82
  • HY-W414334

    DNA/RNA Synthesis Fluorescent Dye Cancer
    ICR-191 dihydrochloride enhances Cisplatin (HY-17394)- DNA binding and sensitizes cells to cisplatin. ICR-191 dihydrochloride induces a significant increase in the expression of phosphorylated H2AX (γH2AX), particularly in DNA-replicating cells. ICR-191 dihydrochloride can be used for the study of leukemia .
    ICR-191 dihydrochloride
  • HY-154978

    Drug Derivative Cancer
    Cisplatin-resistant cells-IN-1 (Compound 8) has high cytotoxicity against Cisplatin (HY-17394)-resistant cells. Cisplatin-resistant cells-IN-1 reduces the metabolic activity effectively in the low nanomolar range (IC50: 0.14-1.79 μM in A549/A549-R, K562/K562-R, and MCF-7/MCF-7TamR cells) .
    Cisplatin-resistant cells-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: